EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacogenetics of Efavirenz Exposure in Cervicovaginal Fluid during Pregnancy and Postpartum

Oluwasegun Eniayewu iD, Uche Azuka, Jonah Ogah, Ebunoluwa Adejuyigbe iD, Oluseye Bolaji iD, Adeniyi Olagunju iD

Clinical Pharmacology & Therapeutics · 2024

DOI: 10.1002/cpt.3343 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Oluwasegun Eniayewu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Ilorin, Ilorin, Nigeria. Hauptthemen laut MEDLINE: Benzoxazines, Alkynes, Cyclopropanes, Cytochrome P-450 CYP2B6. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this study, we investigated the combined influence of pregnancy and genetic polymorphisms on efavirenz pharmacokinetics in cervicovaginal fluid (CVF) of women receiving antiretroviral therapy. Women receiving efavirenz‐containing antiretroviral therapy were recruited from two hospitals in Nigeria during 2017–2020. Sparse CVF and plasma samples were obtained during pregnancy to assess the possible association between drug concentration and CYP2B6 polymorphisms (stage I). Participants were stratified into three CYP2B6 516G>T ( rs3745274) genotype groups and re‐enrolled for intensive pharmacokinetic sampling (stage II). Overall, 159 women (142 pregnant and 12 postpartum) contributed samples in stage I (88 CVF, 81 plasma and 73 paired). CYP2B6 516G>T (rs3745274) remained independently associated with log 10 efavirenz CVF concentration during pregnancy after adjusting for plasma concentration, with β (Log 10 efavirenz concentration, 95%CI) of 0.204 (0.027, 0.382), P = 0.025). Median (IQR) efavirenz C min in CVF during pregnancy ( n = 12) vs. postpartum ( n = 12) was 243 ng/mL (168–402) vs. 447 ng/mL (159–974), C max was 1,031 ng/mL (595–1,771) vs. 1,618 ng/mL (675–2,695), and AUC 0‐24h was 16,465 ng.h/mL (9,356–30,417) vs. 30,715 ng.h/mL (10,980–43,714). CVF‐to‐plasma AUC ratio was 0.36 during pregnancy and 0.46 postpartum. Upon stratification, efavirenz clearance during pregnancy was 57.9% higher than postpartum in patients with the CYP2B6 516GT genotype; the AUC 0‐24h and C max were 33.8% and 8.6% lower, respectively. Efavirenz C min in CVF exceeded the protein binding‐adjusted IC 90 (PBIC 90 ) of 126 ng/mL during pregnancy and postpartum. Efavirenz is well distributed into the CVF; both pregnancy and CYP2B6 polymorphisms affect the extent of exposure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzoxazinesAlkynesCyclopropanesCytochrome P-450 CYP2B6Postpartum PeriodHIV InfectionsAnti-HIV AgentsHumansFemalePregnancyAdultVaginaNigeriaYoung AdultCervix UteriPolymorphism, Single NucleotideGenotypePharmacogeneticsBody FluidsReverse Transcriptase InhibitorsPregnancy Complications, Infectious

Substanzen

efavirenzBenzoxazinesAlkynesCyclopropanesCytochrome P-450 CYP2B6CYP2B6 protein, humanAnti-HIV AgentsReverse Transcriptase Inhibitors

Autor:innen und Institutionen

  • Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Ilorin, Ilorin, Nigeria.
  • Federal Medical Centre, Makurdi, Nigeria.
  • Department of Paediatrics and Child Health, Faculty of Clinical Sciences, Obafemi Awolowo University, Ile-Ife, Nigeria.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria.
  • Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.

ORCID-Profile: Oluwasegun Eniayewu, Ebunoluwa Adejuyigbe, Oluseye Bolaji, Adeniyi Olagunju

Förderung

  • Wellcome Trust

Zitieren

APA

Eniayewu, O., Azuka, U., Ogah, J., Adejuyigbe, E., Bolaji, O., & Olagunju, A. (2024). Pharmacogenetics of Efavirenz Exposure in Cervicovaginal Fluid during Pregnancy and Postpartum. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3343

Vancouver

Eniayewu O, Azuka U, Ogah J, Adejuyigbe E, Bolaji O, Olagunju A. Pharmacogenetics of Efavirenz Exposure in Cervicovaginal Fluid during Pregnancy and Postpartum. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3343

BibTeX
@article{Eniayewu2024,
  author = {Eniayewu, Oluwasegun and Azuka, Uche and Ogah, Jonah and Adejuyigbe, Ebunoluwa and Bolaji, Oluseye and Olagunju, Adeniyi},
  title = {Pharmacogenetics of Efavirenz Exposure in Cervicovaginal Fluid during Pregnancy and Postpartum},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1002/cpt.3343}
}
Kostenlos starten →